Synaptogenic peptides
A small but distinctive class of research peptides drives the formation of new synaptic connections directly, rather than indirectly through neurotrophin induction. This page collects them, explains the two main mechanistic pathways (c-Met and FGFR1), and addresses the safety questions that come with chronic agonism of growth-factor systems.
What synaptogenesis means
The cellular event
Synaptogenesis is the formation of new synaptic connections between neurons. Most active during development, it persists at lower rates throughout adult life and provides part of the substrate for ongoing learning and recovery from neural injury. A synaptogenic compound is one that drives the cellular machinery of new-synapse formation directly — typically by promoting dendritic spine growth on the postsynaptic neuron and stabilising the protein scaffolds that anchor the new connection.
This is mechanistically distinct from BDNF induction. BDNF stabilises synapses that activity has already engaged, supporting the learning loop. Synaptogenic agents create new structural substrate that wasn't there before. The two effects can be complementary in a research design but they answer different questions.
In published research, synaptogenic peptides have produced some of the most striking cognitive-recovery results in aged-animal models — partial restoration of performance on learning tasks back to young-control levels. The mechanism is rigorous; the translational distance from rodent paradigms to human application is substantial and has not yet been bridged.
The two pathways
c-Met vs FGFR1
The c-Met pathway (Dihexa)
c-Met is a receptor tyrosine kinase whose physiological ligand is hepatocyte growth factor (HGF). When activated in the CNS, c-Met signalling drives dendritic spine formation. Dihexa is a small-peptide HGF mimetic that activates c-Met at picomolar concentrations — published work reports synaptogenic potency several orders of magnitude beyond BDNF in equivalent assays.
The pathway is also implicated in oncogenic processes when chronically dysregulated. Long-term safety of pharmacological c-Met agonism in humans is uncharacterised, which is the chief brake on clinical development of the compound.
The FGFR1 pathway (FGL)
FGFR1 is the principal CNS receptor for fibroblast growth factor and the binding partner of the neural cell adhesion molecule (NCAM). Activation drives neurite outgrowth and synapse maturation through PI3K-Akt and MAPK signalling. FGL is a 15-amino-acid mimetic of NCAM's key functional motif, designed to engage FGFR1 directly.
Like c-Met, FGFR1 is implicated in oncogenic signalling when dysregulated, raising the same theoretical safety concern around chronic activation. The Copenhagen group that developed FGL has done substantial mechanistic work; the clinical translation has not progressed.
The family
Peptides in the synaptogenic class
Dihexa
An orally active hexapeptide derivative of angiotensin IV, characterised in academic research as among the most potent known pro-cognitive compounds in animal models.
FGL Peptide
A 15-amino-acid peptide mimetic of the FGL loop of the neural cell adhesion molecule (NCAM), studied for neurogenic, synaptogenic, and memory-enhancing effects in cellular and animal research.
The honest safety question
Why these compounds remain preclinical
Both principal synaptogenic pathways — c-Met and FGFR1 — sit at the centre of the growth-factor receptor biology that, when dysregulated, drives tumour proliferation and metastasis. Pharmacological agonism of these receptors is mechanistically equivalent in some respects to what aberrant growth-factor signalling does in oncogenesis. The difference is dose, duration, and the regulatory feedback that healthy tissue retains. Whether that difference is sufficient to make chronic pharmacological agonism safe over years of exposure is an open question.
No published long-term toxicology data in any species exists for chronic Dihexa or FGL administration. No human clinical trials of either compound are publicly registered. This is the principal reason these compounds remain laboratory tools and have not progressed to clinical development despite the strong mechanistic data.
Read the synaptogenic peptides as research instruments for understanding adult neural plasticity, not as candidate therapeutics. The science is meaningful; the safety characterisation is not yet adequate for the translation step.